Replies to post #9474 on Momenta Pharmaceuticals, Inc. (MNTA)

[pollyvonwog]

Solid revenue from enox, but expenses were certainly on the high end at 32.4m (2.9m from litigation). Wasn't RS's top end range 28m?

Also, this is pretty interesting... Does the one below fall into the profit split category?

Momenta announced today that Baxter selected a third biosimilar product to be developed under the collaboration. Momenta has initiated development of this product, a monoclonal antibody for oncology, which has been designated as M511.

[DewDiligence]

MNTA had an effective cash balance of $412M at 6/30/12: #msg-78117222.

[DewDiligence]

Annotations on the 3Q12 PR and CC: #msg-81239852.